Optic atrophy is a degenerative disease of the optic nerve that leads to gradual damage to the retinal ganglion cells - the nerve cells that transmit visual signals from the retina to the brain. The ...

Stoke Therapeutics (NASDAQ:STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). FALCON is a ...

A research team from the Medical University of Vienna and the Medical University of Graz has discovered a previously unknown genetic cause of hereditary optic atrophy, a degenerative disease of the ...

A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic neuropathy (LHON). The study was conducted in collaboration with the Seoul National ...

Dr. Amy E. Armstrong-Javors: A 12-year-old boy with autism was admitted to this hospital because of decreased vision in both eyes. The patient had been in his usual state of health until 6 weeks ...

– Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments – – ADOA is a ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...

Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood by way of blurry vision, trouble reading or ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...

Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood by way of blurry vision, trouble reading or ...